EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sulbactam-durlobactam susceptibility test method development and quality control ranges for MIC and disk diffusion tests

Sarah M McLeod iD, Nicole M Carter iD, Michael D Huband iD, Maria M Traczewski, Patricia A Bradford iD, Alita A Miller iD

Journal of Clinical Microbiology · 17.01.2024 · 62 (1)

DOI: 10.1128/jcm.01228-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Microbiology, erschienen am 17.01.2024. Verfasst von Sarah M McLeod und 5 weiteren Autor:innen. Beteiligte Einrichtung: Entasis Therapeutics Inc. (an affiliate of Innoviva Specialty Therapeutics, Inc.), Waltham, Massachusetts, USA. Hauptthemen laut MEDLINE: Sulbactam, Acinetobacter baumannii, Azabicyclo Compounds. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Entasis Therapeutics (Entasis Therapeutics Inc.).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sulbactam-durlobactam is a β-lactam/β-lactamase inhibitor combination developed to treat hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex (ABC). Durlobactam is a diazabicyclooctane β-lactamase inhibitor with potent activity against Ambler classes A, C, and D serine β-lactamases and restores sulbactam activity against multidrug-resistant ABC. Studies were conducted to establish sulbactam-durlobactam antimicrobial susceptibility testing methods for both broth microdilution minimal inhibitory concentration (MIC) and disk diffusion tests as well as quality control (QC) ranges. To establish the MIC test method, combinations of sulbactam and durlobactam were evaluated using a panel of genetically characterized A. baumannii isolates which were categorized as predicted to be susceptible or resistant based on the spectrum of β-lactamase inhibition by durlobactam. MIC testing with doubling dilutions of sulbactam with a fixed concentration of 4 µg/mL of durlobactam resulted in the greatest discrimination of the pre-defined susceptible and resistant strains. Similarly, the sulbactam/durlobactam 10/10 µg disk concentration showed the best discrimination as well as correlation with the MIC test. A. baumannii NCTC 13304 was selected for QC purposes because it assesses the activity of both sulbactam and durlobactam with clear endpoints. Multi-laboratory QC studies were conducted according to CLSI M23 Tier 2 criteria. A sulbactam-durlobactam broth MIC QC range of 0.5/4–2/4 µg/mL and a zone diameter QC range of 24–30 mm were determined for A. baumannii NCTC 13304 and have been approved by CLSI. These studies will enable clinical laboratories to perform susceptibility tests with accurate and reproducible methods.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SulbactamAcinetobacter baumanniiAzabicyclo CompoundsHumansAnti-Bacterial Agentsbeta-Lactamase InhibitorsMicrobial Sensitivity TestsQuality ControlDrug Combinations

Stichwörter der Autor:innen

quality controlsulbactam-durlobactamsusceptibility testing

Substanzen

sulbactam-durlobactamSulbactamAnti-Bacterial Agentsbeta-Lactamase InhibitorsdurlobactamDrug CombinationsAzabicyclo Compounds

Autor:innen und Institutionen

  • Entasis Therapeutics Inc. (an affiliate of Innoviva Specialty Therapeutics, Inc.), Waltham, Massachusetts, USA.
  • JMI Labs, North Liberty, Iowa, USA.
  • Clinical Microbiology Institute, Wilsonville, Oregon, USA.
  • Antimicrobial Development Specialists, LLC, Nyack, New York, USA.

ORCID-Profile: Sarah M McLeod, Nicole M Carter, Michael D Huband, Patricia A Bradford, Alita A Miller

Förderung

  • Entasis Therapeutics (Entasis Therapeutics Inc.)

Zitieren

APA

McLeod, S. M., Carter, N. M., Huband, M. D., Traczewski, M. M., Bradford, P. A., & Miller, A. A. (2024). Sulbactam-durlobactam susceptibility test method development and quality control ranges for MIC and disk diffusion tests. Journal of Clinical Microbiology, 62(1). https://doi.org/10.1128/jcm.01228-23

Vancouver

McLeod SM, Carter NM, Huband MD, Traczewski MM, Bradford PA, Miller AA. Sulbactam-durlobactam susceptibility test method development and quality control ranges for MIC and disk diffusion tests. Journal of Clinical Microbiology. 2024;62(1). doi:10.1128/jcm.01228-23

BibTeX
@article{McLeod2024,
  author = {McLeod, Sarah M and Carter, Nicole M and Huband, Michael D and Traczewski, Maria M and Bradford, Patricia A and Miller, Alita A},
  title = {Sulbactam-durlobactam susceptibility test method development and quality control ranges for MIC and disk diffusion tests},
  journal = {Journal of Clinical Microbiology},
  year = {2024},
  volume = {62},
  number = {1},
  doi = {10.1128/jcm.01228-23}
}
Kostenlos starten →